MRC1 and neoplasm: M2 expresses high levels of CD163, CD206, CCL18, and CCL22, releasing anti-inflammatory (TGF-β, IL-4, and IL-13) and inflammatory (IL-6, IL-12, and TNF-α) factors, as well as tumor-promoting arginase-1 and VEGF, modulated by TME signals [68].